Neurobiological Operating Cycle from 2010 to 2026
| NTII Stock | USD 0.0001 0.00 0.00% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 2.93 | Current Value 2.78 | Quarterly Volatility 834.0415854 |
Check Neurobiological Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurobiological Technologies' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 1.3 M or Research Development of 12.9 M, as well as many indicators such as Price To Sales Ratio of 0.75, Dividend Yield of 0.0 or PTB Ratio of 0.84. Neurobiological financial statements analysis is a perfect complement when working with Neurobiological Technologies Valuation or Volatility modules.
Neurobiological | Operating Cycle | Build AI portfolio with Neurobiological Stock |
The Operating Cycle trend for Neurobiological Technologies offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Neurobiological Technologies is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Neurobiological Technologies' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Neurobiological Technologies over the last few years. It is Neurobiological Technologies' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurobiological Technologies' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Neurobiological Operating Cycle Regression Statistics
| Arithmetic Mean | 204.87 | |
| Geometric Mean | 3.95 | |
| Coefficient Of Variation | 407.10 | |
| Mean Deviation | 380.77 | |
| Median | 2.55 | |
| Standard Deviation | 834.04 | |
| Sample Variance | 695,625 | |
| Range | 3.4K | |
| R-Value | (0.41) | |
| Mean Square Error | 618,372 | |
| R-Squared | 0.17 | |
| Significance | 0.10 | |
| Slope | (67.42) | |
| Total Sum of Squares | 11.1M |
Neurobiological Operating Cycle History
About Neurobiological Technologies Financial Statements
Investors use fundamental indicators, such as Neurobiological Technologies' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Neurobiological Technologies' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 2.93 | 2.78 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Neurobiological Technologies Correlation against competitors. For more detail on how to invest in Neurobiological Stock please use our How to Invest in Neurobiological Technologies guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is there potential for Biotechnology market expansion? Will Neurobiological introduce new products? Factors like these will boost the valuation of Neurobiological Technologies. Anticipated expansion of Neurobiological directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Neurobiological Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Neurobiological Technologies's market price often diverges from its book value, the accounting figure shown on Neurobiological's balance sheet. Smart investors calculate Neurobiological Technologies' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Neurobiological Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Neurobiological Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurobiological Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Neurobiological Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.